Charco Neurotech is a multi-award winning medical technology company established in 2019 as a spinout from Imperial College London.
Its first therapeutic device, CUE1, provides life-changing neuromodulation therapy for people with Parkinson’s. This neurodegenerative disorder affects 10 million people worldwide and despite the best available medical and surgical interventions, people with Parkinson’s are often frustrated, as they remain significantly limited in their activities. Based on more than two years’ research with patients and clinicians, the discrete, non-invasive CUE1 wearable device delivers individualised peripheral nerve stimulation designed to alleviate motor symptoms such as slowness, stiffness and freezing while walking. The company’s mission is to improve the quality of life for all people with Parkinson’s.